As an anti-VEGF agent, Bevacizumab combined with ICIs can not only inhibit tumor angiogenesis but also remodel the immunosuppressive tumor microenvironment, facilitating the recruitment and proliferation of immune cells, thereby promoting immune response (43). Here, VEGFA is linked to neoplasm.